Clinical trials
Immunosuppression clinical trials
Below are recruiting immunosuppression clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06881927RecruitingPhase 4
Reducing anti-rejection meds in ICU for kidney transplant patients
This study tests whether quickly reducing your anti-rejection medicines during a life-threatening ICU stay can help your kidneys recover and improve your overall outcome. It is for kidney transplant recipients with septic shock or severe breathing failure.
StrasbourgAges 18 years+ - NCT06336863Enrolling by invitation
DNA test to help kidney transplant patients switch to a single anti-rejection drug
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
Dallas, TexasAges 18 years+ - NCT07206277Recruiting
Using Fibroscan to guide lower anti-rejection medicine after liver transplant
This trial uses a special ultrasound (Fibroscan) to check your liver health and see if you can safely reduce your anti-rejection medications. It is for people who are at least 2 years past a liver transplant and whose liver is working well.
Edmonton, AlbertaAges 18 years+ - NCT07735650Enrolling by invitation
Safe withdrawal of immune meds after liver transplant
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
TaoyuanAges 20 years+ - NCT05043870RecruitingPhase 4
Testing medicines that calm the immune system in kids with Crohn’s
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
Shanghai, Shanghai MunicipalityAges 6–18 - NCT06695741RecruitingPhase 2
Lower dose cyclophosphamide with standard therapy for severe aplastic anemia
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
Tianjin, Tianjin MunicipalityAges 12 years+ - NCT06354179RecruitingPhase 4
Once-daily immunosuppression after liver transplant
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
BesançonAges 18 years+ - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT04877288RecruitingPhase 3
Switch some teen kidney transplant patients to belatacept
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
Birmingham, AlabamaAges 12–17 - NCT03399175Recruiting
Early immune-suppressing treatment for VKH eye disease
This trial studies giving immune-suppressing treatment early in Vogt-Koyanagi-Harada (VKH) disease to see if it improves outcomes. It may help people reduce ongoing eye inflammation if they qualify and can be followed for a longer time.
São Paulo, São PauloAges 10–70 - NCT04182984Recruiting
Compare immunosuppressant medicines for eye-only myasthenia gravis
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
Xi'an, ShaanxiAges 18–75 - NCT04654988RecruitingPhase 4
Immunosuppression study for active myocarditis or inflammatory cardiomyopathy
This Phase 4 study tests whether weakening the immune system (immunosuppression) works better for people with active myocarditis or inflammatory cardiomyopathy. It includes extra heart tests—two heart muscle biopsies and two heart MRI scans—to confirm the diagnosis and guide treatment.
WarsawAges 18–65 - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+ - NCT06676696RecruitingPhase 4
Stopping immunosuppression after failed kidney transplant
This study compares what happens when patients with a failed kidney transplant (still in the body) stop their immunosuppressant medicines at 6 months versus continuing them. The goal is to safely prevent your immune system from becoming too sensitive, which can make finding a new donor kidney harder.
BarcelonaAges 18 years+ - NCT06694740RecruitingPhase 2/Phase 3
Interferon gamma for immune recovery in the ICU
This trial tests if a drug called interferon gamma can help boost the immune system of patients in the ICU who are fighting serious infections. It is for adults who are on a breathing machine and have low immune function.
ParisAges 18 years+ - NCT07074951Recruiting
Tonsillectomy and immune therapy for high-risk IgA kidney disease
This trial tests whether removing the tonsils (tonsillectomy) plus immune-suppressing therapy can help people with a high-risk form of IgA nephropathy, a kidney disease. It aims to slow down kidney damage and delay the need for dialysis.
Saint PetersburgAges 18–75 - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT06532890Recruiting
Using microRNAs to personalize heart transplant medicines in children
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Aurora, ColoradoAges Up to 18 years - NCT01889381RecruitingPhase 2
Transplanting facial and jaw bone using donor tissue
This trial studies a special surgery to replace part of the skull, face, and jaw using donor tissue. It also tests medicines to help your body accept the transplant, aiming to restore function and appearance after serious injury.
Baltimore, MarylandAges 18–65 - NCT07775235Recruiting
Treatment outcomes for muscle inflammation with rapid lung disease
This study looks at how well treatments work for people with muscle inflammation (myositis) that causes a fast-progressing lung condition. It may help doctors find better ways to manage this serious combination.
SingaporeAges 21 years+ - NCT07430306RecruitingPhase 3
Study of anifrolumab for lupus patients not yet on strong treatments
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Anniston, AlabamaAges 18–70 - NCT07302776RecruitingPhase 1
Stopping immune suppression after stem cell transplant
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
Palo Alto, CaliforniaAges 18–80 - NCT06047171RecruitingPhase 2
Testing ALE.F02 for new kidney inflammation from vasculitis
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
PragueAges 18 years+ - NCT06939751Recruiting
Testing microRNA levels to personalize heart transplant care
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
Los Angeles, CaliforniaAges 18–99
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunosuppression?
- Yes. Clin2 currently lists 95 recruiting immunosuppression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunosuppression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunosuppression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.